Research & Development



  秋收節也就是秋分,《春秋繁露?陰陽出入上下篇》中說︰“秋分者,陰陽相半也,故晝夜均而寒暑平。”   霍光點頭道︰“確實很有用。”福利彩票软件下载   雲瑯信誓旦旦的道。168彩票app手机版   听甦稚提到了甦子良,雲瑯冷笑一聲道︰“我派人告訴你父親你母親跟甦煥的消息,還帶去了甦煥的親筆信,結果,第二天,你父親就消失了,十五天之後又在邯鄲出現,估計他想找一個我找不到他的地方安身立命。至于你的母親跟弟弟,估計已經被他舍棄了。”   雲音一邊流淚,一邊哽咽著不斷安慰霍光莫哭,莫哭。168彩票安装   霍去病瞅瞅大殿外黑漆漆的天空憂傷的道︰“天亮之後,路博德就應該發起進攻了……”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo